Start Preamble

AGENCY:

Office of the Assistant Secretary of Defense for Health Affairs, DoD.

ACTION:

Notice.

SUMMARY:

In compliance with Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995, the Office of the Assistant Secretary of Defense for Health Affairs announces a proposed new public information collection and seeks public comment on the provisions thereof. Comments are invited on: (a) Whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency's estimate of the burden of the proposed information collection; (c) ways to enhance the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the information collection on respondents, including through the use of automated collection techniques or other forms of information technology.

DATES:

Consideration will be given to all comments received by May 16, 2011.

ADDRESSES:

You may submit comments, identified by docket number and title, by any of the following methods:

• Federal eRulemaking Portal: http://www.regulations.gov. Follow the instructions for submitting comments.
• Mail: Federal Docket Management System Office, 1160 Defense Pentagon, OSD Mailroom 3C843, Washington, DC 20301-1160.

Instructions: All submissions received must include the agency name, docket number and title for this Federal Register document. The general policy for comments and other submissions from members of the public is to make these submissions available for public viewing on the Internet at http://www.regulations.gov as they are received without change, including any personal identifiers or contact information.

Start Further Info

FOR FURTHER INFORMATION CONTACT:

To request more information on this proposed information collection or to obtain a copy of the proposal and associated collection instruments, please write to Naval Health Research Center, DoD Center for Deployment Health Research, Department 164, ATTN: Tyler C. Smith, MS, PhD, 140 Sylvester Rd., San Diego, CA 92106-3521, or call (619) 553-7593.

Title; Associated Form; and OMB Number: ACAM2000® Myopericarditis Registry; OMB Control Number 0720-TBD.

Needs and Uses: The Food and Drug Administration required the establishment of several Phase IV post-licensure studies to evaluate the long-term safety of ACAM2000® smallpox vaccine. Among the required post-licensure studies is the establishment of a myopericarditis registry. The ACAM2000® Myopericarditis Registry is designed to study the natural history of myopericarditis following receipt of the ACAM2000® vaccine, including evaluating factors that may influence disease prognosis, thus addressing the FDA post-licensure requirement and ensuring the continued licensing of this vaccine.

Affected Public: Civilians, former Active Duty or active Guard/Reserve in the U.S. Military, who received the ACACM2000® smallpox vaccine while in the military and subsequently developed signs or symptoms of myopericarditis.

Annual Burden Hours: 20.

Number of Respondents: 20.

Responses per Respondent: 2.

Average Burden per Response: 30 minutes.

Frequency: Semi-annually.

End Further Info End Preamble Start Supplemental Information

SUPPLEMENTARY INFORMATION:

Summary of Information Collection

Eligible respondents are civilians who are former Active Duty or active Guard/Reserve in the U.S. Military that received the ACACM2000® smallpox vaccine while in the military and subsequently developed signs or symptoms of myopericarditis. The information collected will illuminate the natural history of post-vaccine myopericarditis and evaluate factors that may influence disease prognosis. Inclusion of civilians who were formerly in the military in addition to current military members is imperative in order to obtain information on those who may have separated from the military due to their medical condition. Conducting this Registry will ensure the continued licensure of this military relevant vaccine.

Start SignatureEnd Signature End Supplemental Information